23 August 2018 | News
DexCom expects to launch the first automated insulin delivery system using TypeZero's InControl algorithm in 2019.
Singapore- DexCom, leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies. TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery.
Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens. The companies share a consistent vision to improve the lives of people with diabetes through innovation.
“As the first iCGM designated by the FDA, Dexcom again has the opportunity to lead the market for integrated systems for diabetes management. TypeZero is a great fit for Dexcom as we look to deliver a growing set of tools to both our insulin delivery partners and our customers,” said Steve Pacelli, Dexcom’s Executive Vice President of Strategy & Corporate Development. “Combined with best-in-class CGM technology, we believe TypeZero’s technology and strong team will accelerate our efforts to further differentiate Dexcom’s portfolio.”
Dexcom currently expects to support the first commercial launch of an AID system using the inControl algorithm in 2019.